{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:07:48Z","timestamp":1759018068894,"version":"3.44.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1053\/jinf.2002.1103","type":"journal-article","created":{"date-parts":[[2003,3,15]],"date-time":"2003-03-15T07:29:29Z","timestamp":1047713369000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["HIV-associated Lipodystrophy Syndrome: Assessment and Management"],"prefix":"10.1016","volume":"46","author":[{"given":"N.","family":"Bodasing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/jinf.2002.1103_RF1","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(05)79053-X","article-title":"Severe premature coronary artery disease with protease inhibitors","volume":"351","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/0003-4819-131-7-199910050-00032","article-title":"Myocardial infarction in HIV-infected men receiving protease inhibitors","volume":"131","author":"Flynn","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/jinf.2002.1103_RF3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(05)78644-X","article-title":"Vascular complications associated with use of HIV protease inhibitors","volume":"351","author":"Vittecoq","year":"1998","journal-title":"Lancet"},{"article-title":"Impact of treatment with protease inhibitors (PI) on myocardial infarction (MI) occurrence in HIV-infected men","year":"2001","author":"Mary-Krause","key":"10.1053\/jinf.2002.1103_RF4"},{"article-title":"Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?","year":"2001","author":"Klein","key":"10.1053\/jinf.2002.1103_RF5"},{"key":"10.1053\/jinf.2002.1103_RF6","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1097\/00002030-200011100-00001","article-title":"Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors","volume":"14","author":"Maggi","year":"2000","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF7","first-page":"82","article-title":"Increased carotid intima-media thickness in women with HIV lipodystrophy","volume":"6","author":"Wilkie","year":"2001","journal-title":"Antiviral Ther"},{"key":"10.1053\/jinf.2002.1103_RF8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/jinf.2002.1103_RF9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/oxfordjournals.aje.a009302","article-title":"Association of coronary heart disease incidence with carotid artery wall thickness and major risk factors: the atherosclerosis Risk in Communities (ARIC) Study, 1987\u20131993","volume":"146","author":"Chambless","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1053\/jinf.2002.1103_RF10","first-page":"11","article-title":"Dyslipidaeimia due to HIV infection and its therapy","volume":"4","author":"Grunfeld","year":"1999","journal-title":"Antiviral Ther"},{"article-title":"Perspective of HIV-associated coronary heart disease","year":"2002","author":"Lungdren","key":"10.1053\/jinf.2002.1103_RF11"},{"key":"10.1053\/jinf.2002.1103_RF12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-9343(99)00169-2","article-title":"Acute pancreatitis in human immunodeficiency-infected patents: a review","volume":"107","author":"Dassopoulos","year":"1999","journal-title":"Am J Med"},{"key":"10.1053\/jinf.2002.1103_RF13","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00002030-199906180-00025","article-title":"Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors","volume":"13","author":"Meyer","year":"1999","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF14","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1097\/00002030-199910010-00036","article-title":"Avascular necrosis in HIV infection","volume":"13","author":"Johns","year":"1999","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF15","first-page":"546","article-title":"Psychosocial impact of the lipodystrophy syndrome in HIV infection","volume":"10","author":"Collins","year":"2000","journal-title":"AIDS Read"},{"key":"10.1053\/jinf.2002.1103_RF16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1468-1293.2000.00024-125.x","article-title":"Measuring insulin sensitivity in HIV-infected patients using the hyperinsulinaemic euglycaemic clamp technique","volume":"1","author":"Bodasing","year":"2002","journal-title":"HIV Med"},{"key":"10.1053\/jinf.2002.1103_RF17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1053\/jinf.2002.1103_RF18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/qjmed\/92.7.379","article-title":"Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods","volume":"92","author":"Haq","year":"1999","journal-title":"Q J Med"},{"key":"10.1053\/jinf.2002.1103_RF19","first-page":"589","article-title":"Managing metabolic disturbances and lipodystrophy: diet, excurses and smoking advice","volume":"11","author":"Moyle","year":"2001","journal-title":"AIDS Read"},{"key":"10.1053\/jinf.2002.1103_RF20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.7326\/0003-4819-133-5-200009050-00010","article-title":"Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomised, controlled trial","volume":"133","author":"Grinspoon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1053\/jinf.2002.1103_RF21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.7326\/0003-4819-125-11-199612010-00002","article-title":"Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group","volume":"125","author":"Schambelan","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1053\/jinf.2002.1103_RF22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1210\/jcem.87.2.8391","article-title":"Effects of recombinant human growth hormone on hepatic liver and carbohydrate metabolism in HIV-infected patients with fat accumulation","volume":"87","author":"Schwarz","year":"2002","journal-title":"J Clin Endocrin Metab"},{"article-title":"Benefit of polylactic acid implant (New Fill) in severe facial lipoatrophy in HIV infected patients: preliminary results of the Vega Study","year":"2001","author":"Aubron-Olivier","key":"10.1053\/jinf.2002.1103_RF23"},{"key":"10.1053\/jinf.2002.1103_RF24","first-page":"75","article-title":"Facial implants with polymethyl-methylcrylate for lipodystrophy correction: 30 months follow up","volume":"6","author":"Serra","year":"2001","journal-title":"Antiviral Ther"},{"key":"10.1053\/jinf.2002.1103_RF25","first-page":"74","article-title":"Successful surgical therapy with polyvinyl gel microspheres of severe facial lipoatrophy: results after one year of follow up","volume":"6","author":"Del Pino","year":"2001","journal-title":"Antiviral Ther"},{"key":"10.1053\/jinf.2002.1103_RF26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(99)01172-1","article-title":"Liposuction for protease-inhibitor-associated lipodystrophy","volume":"353","author":"Ponce-de-Leon","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(98)00022-1","article-title":"Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(98)00016-3","article-title":"Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?","volume":"80","author":"Christians","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1053\/jinf.2002.1103_RF29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200005050-00006","article-title":"Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","article-title":"The Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"Ruiz","year":"2001","journal-title":"J Acquir Immun Def Syndr"},{"key":"10.1053\/jinf.2002.1103_RF32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine","volume":"13","author":"Martinez","year":"1999","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/317426","article-title":"Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy","volume":"31","author":"Martinez","year":"2000","journal-title":"Clin Infect Dis"},{"article-title":"Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz","year":"2000","author":"Bonnet","key":"10.1053\/jinf.2002.1103_RF34"},{"key":"10.1053\/jinf.2002.1103_RF35","unstructured":"Blanco, F, Casimiro, C, Gomez, F, et al., Metabolic outcome in HIV-positive patients after switching PI to NNRTI, 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV"},{"article-title":"Improvement of Lipodystrophy in HIV-1 infected subjects switching from 2NRTI\/PI to 2NRTI\/Abacavir","year":"2000","author":"Rozenbaum","key":"10.1053\/jinf.2002.1103_RF36"},{"key":"10.1053\/jinf.2002.1103_RF37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/jinf.2002.1103_RF38","first-page":"413","article-title":"Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir","volume":"6","author":"Walli","year":"2001","journal-title":"Eur J Med Res"},{"key":"10.1053\/jinf.2002.1103_RF39","first-page":"20","article-title":"Comparison of the metabolic disorders and clinical lipodystrophy 48 weeks after switching from highly active antiretroviral therapy to TRIZIVIR versus continued highly active antiretroviral therapy. (TRIZAL: AZL30002)","volume":"6","author":"Lafeuillade","year":"2001","journal-title":"Antiviral Ther"},{"article-title":"A randomised, controlled, open-label study of revision of anti-retroviral regimens containing stavudine (d4T) and\/or a protease inhibitor (PI) to zidovudine (ZDV)\/lamivudine (3TC)\/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data","year":"2002","author":"John","key":"10.1053\/jinf.2002.1103_RF40"},{"article-title":"Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV)","year":"2002","author":"McComsey","key":"10.1053\/jinf.2002.1103_RF41"},{"key":"10.1053\/jinf.2002.1103_RF42","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/jinf.2002.1103_RF44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1053\/jinf.2002.1103_RF45","first-page":"32","article-title":"A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes","volume":"6","author":"Calmy","year":"2001","journal-title":"Antiviral Ther"},{"key":"10.1053\/jinf.2002.1103_RF46","first-page":"82","article-title":"Use of PPRA-(gamma) modulator rosiglitazone in normoglycaemic patients with HIV-lipodystrophy syndrome","volume":"6","author":"Visnegarwala","year":"2002","journal-title":"Antiviral Ther"},{"key":"10.1053\/jinf.2002.1103_RF47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001432-200202000-00005","article-title":"Hyperlactaema syndromes in people with HIV infection","volume":"15","author":"John","year":"2002","journal-title":"Curr Opinion Infect Dis"},{"key":"10.1053\/jinf.2002.1103_RF48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00002030-200104130-00016","article-title":"Management of hyperlactaemia: no need for routine lactate measurements","volume":"15","author":"Brinkman","year":"2001","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(05)60266-8","article-title":"Riboflavin to treat nucleoside analogue-induced lactic acidosis","volume":"352","author":"Fouty","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF50","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/00002030-199710001-00003","article-title":"Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report","volume":"11","author":"Lenzo","year":"1997","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-199702000-00008","article-title":"Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with with antiretroviral nucleoside analogues","volume":"11","author":"Famularo","year":"1997","journal-title":"AIDS"},{"key":"10.1053\/jinf.2002.1103_RF52","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF53","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/jinf.2002.1103_RF54","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/00005768-199704000-00020","article-title":"Body composition by DEXA in older adults: accuracy and influence of scan mode","volume":"29","author":"Clasey","year":"1997","journal-title":"Med Sci Sports Exerc"},{"key":"10.1053\/jinf.2002.1103_RF55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","article-title":"Visceral abdominal-fat accumulation associated with use of indinavir","volume":"351","author":"Miller","year":"1998","journal-title":"Lancet"},{"article-title":"Comparison of Abdominal Fat Distribution in HIV +ve patients with and without clinical fat redistribution and HIV \u2212ve patients, using computerised tomography","year":"2000","author":"Burn","key":"10.1053\/jinf.2002.1103_RF56"},{"key":"10.1053\/jinf.2002.1103_RF57","article-title":"Detection of occult wasting by BIA technology","volume":"10","author":"Muurahainen","year":"1994","journal-title":"Programs and Abstracts of the X International Conference on AIDS"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445302911035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445302911035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:25:40Z","timestamp":1758986740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445302911035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S0163445302911035"],"URL":"https:\/\/doi.org\/10.1053\/jinf.2002.1103","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2003,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-associated Lipodystrophy Syndrome: Assessment and Management","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/jinf.2002.1103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}